Printer Friendly

TACRINE EFFICACY REAFFIRMED IN NEW STUDY

 TACRINE EFFICACY REAFFIRMED IN NEW STUDY
 PADUA, Italy, July 17 /PRNewswire/ -- The efficacy of tacrine


(Cognex) as a symptomatic treatment of Alzheimer's disease has been confirmed in a parallel-design multicenter study at doses up to 80 mg. per day. This research was presented for the first time at the Third International Conference on Alzheimer's Disease and Related Disorders by Steven Gracon, director of clinical research, CNS for the Parke-Davis division of the Warner-Lambert Company.
 Statistically significant dose response and pairwise comparisons with placebo were demonstrated on both primary measures -- the Alzheimer's Disease Assessment Scale (cognitive subscale) (ADAS-COG) and the investigator-rated Clinical Global Impressions of Change (CGIC). Obtaining statistical significance on both of these outcome measures satisfies prospectively defined criteria for establishing efficacy. Moreover, statistically significant effects were also achieved on a caregiver-rated global impression change of scale.
 "These results reaffirm those of an earlier enriched population design study co-sponsored by the Warner-Lambert Company and the National Institute of Aging," notes Gracon.
 The magnitude of tacrine's clinical effect is clinically important and recognizable to both the study clinician and caregiver. After 12 weeks of double-blind treatment, over 50 percent of patients treated with tacrine 80 mg a day showed improvement of the ADAS Cognitive compared to the decline expected over a six month period in untreated patients. Sixty-three percent of the patients were rated as improved by the study clinician and 56 percent of patients were rated as improved by caregiver.
 The most common advantage events were transaminase elevations which were seen in approximately 25 percent of patients. These elevations are reversible upon discontinuation of therapy.
 The Third International Conference on Alzheimer's Disease and Related Disorders was attended by more than 700 prominent scientists and other experts from 26 countries and every continent. The meeting is held every two years. The 1990 conference took place in Toronto.
 -0- 7/17/92
 /NOTE TO EDITORS: This release has been provided by the Third International Conference on Alzheimer's Disease and Related Disorders through a grant from Du Pont Merck Pharmaceuticals./
 /CONTACT: Linda Murray, 212-468-3256, or Jeffrey Halpern, in Padua, Italy, 011-39-49-866-9390, both for the Third International Conference on Alzheimer's Disease and Related Disorders/ CO: Du Pont Merck Pharmaceuticals ST: Delaware IN: MTC SU:


TS-SH -- NY023 -- 0217 07/17/92 11:36 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 17, 1992
Words:379
Previous Article:ATLANFED BANCORP ANNOUNCES EARNINGS
Next Article:COLONIAL GROUP DECLARES MONTHLY DIVIDEND DISTRIBUTION
Topics:


Related Articles
WARNER-LAMBERT ISSUES STATEMENT FOLLOWING FDA AUTHORIZATION OF EXPANDED ACCESS FOR ALZHEIMER'S DRUG COGNEX
WARNER-LAMBERT ISSUES STATEMENT ON TACRINE STUDY IN NEW ENGLAND JOURNAL
WARNER-LAMBERT ISSUES STATEMENT ON TACRINE STUDY IN NEW ENGLAND JOURNAL
NEW CLINICAL TRIAL DATA FOR ALZHEIMER'S DRUG COGNEX PRESENTED TO FDA ADVISORY COMMITTEE
NATIONAL INSTITUTE ON AGING UNIT ANNOUNCES CLINICAL TRIAL FOR TREATMENT OF ALZHEIMER'S DISEASE
FDA APPROVES ALZHEIMER'S DRUG
CAMBRIDGE NEUROSCIENCE BEGINS MULTINATIONAL DOSE-FINDING STUDY OF CERESTAT(TM) IN STROKE PATIENTS
SMITHKLINE BEECHAM STATEMENT ON NIAID VACCINE TRIALS SHOWING INFANRIX(TM) HIGHLY EFFECTIVE AGAINST PERTUSSIS
Wyeth-Ayerst International to Market New Alzheimer's Disease Treatment

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters